<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>362</serviceExecutionTime><Drug id="75408"><DrugName>emactuzumab</DrugName><DrugNamesKey><Name id="43038725">emactuzumab</Name></DrugNamesKey><DrugSynonyms><Name><Value>CSF-1R huMAb (solid tumors), Roche</Value></Name><Name><Value>anti-CSF1R monoclonal antibody (solid tumors), Roche</Value></Name><Name><Value>emactuzumab</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>RG-7155</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>RO-5509554</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="19446">Roche Holding AG</CompanyOriginator><CompaniesSecondary><Company id="19446">Roche Holding AG</Company></CompaniesSecondary><CrossReferences><SourceEntity id="75408" type="Drug"><TargetEntity id="762438" type="siDrug">Emactuzumab</TargetEntity><TargetEntity id="791140" type="siDrug"></TargetEntity></SourceEntity><SourceEntity id="19446" type="Company"><TargetEntity id="4295890594" type="organizationId">Roche Holding AG</TargetEntity></SourceEntity><SourceEntity id="319" type="ciIndication"><TargetEntity id="10029547" type="MEDDRA"></TargetEntity><TargetEntity id="D008228" type="MeSH"></TargetEntity><TargetEntity id="547" type="ORPHANET"></TargetEntity><TargetEntity id="-1008757452" type="omicsDisease"></TargetEntity><TargetEntity id="703" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3531" type="ciIndication"><TargetEntity id="D013586" type="MeSH"></TargetEntity><TargetEntity id="66627" type="ORPHANET"></TargetEntity><TargetEntity id="-1132862140" type="omicsDisease"></TargetEntity><TargetEntity id="1927" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3154" type="Action"><TargetEntity id="4956" type="Mechanism">Anti-M-CSF</TargetEntity><TargetEntity id="2314" type="Mechanism">CSF1R (c-FMS) Inhibitors</TargetEntity><TargetEntity id="4836" type="Mechanism">Anti-Colony Stimulating Factor 1 Receptor (CSF1R)</TargetEntity></SourceEntity><SourceEntity id="PTGT-00510" type="ciTarget"><TargetEntity id="174052253714363" type="siTarget">Macrophage colony-stimulating factor 1 receptor</TargetEntity><TargetEntity id="471" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="319">Non-Hodgkin lymphoma</Indication><Indication id="3531">Pigmented villonodular synovitis</Indication><Indication id="3713">Advanced solid tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="3154">CSF-1 antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="62255">Anticancer protein kinase inhibitor</Action><Action id="55685">Anticancer monoclonal antibody</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="169">Monoclonal antibody humanized</Technology></Technologies><LastModificationDate>2018-10-29T17:08:22.000Z</LastModificationDate><ChangeDateLast>2018-10-30T00:00:00.000Z</ChangeDateLast><AddedDate>2012-01-07T04:30:42.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="19446" linkType="Company"&gt;Roche&lt;/ulink&gt; was developing emactuzumab (RG-7155; RO-5509554),  a humanized monoclonal antibody targeting the colony stimulating factor-1 receptor (CSF-1R), for the potential iv infusion treatment of advanced solid tumors [&lt;ulink linkID="1252963" linkType="Reference"&gt;1252963&lt;/ulink&gt;], [&lt;ulink linkID="1259334" linkType="Reference"&gt;1259334&lt;/ulink&gt;], [&lt;ulink linkID="1653537" linkType="Reference"&gt;1653537&lt;/ulink&gt;]. In January 2015, a trial of emactuzumab in combination with &lt;ulink linkID="72699" linkType="Drug"&gt;atezolizumab&lt;/ulink&gt; was initiated [&lt;ulink linkID="1629586" linkType="Reference"&gt;1629586&lt;/ulink&gt;]. In April 2016, a phase I trial of emactuzumab in combination with &lt;ulink linkID="94162" linkType="Drug"&gt;selicrelumab&lt;/ulink&gt; (RG-7876) started [&lt;ulink linkID="1763782" linkType="Reference"&gt;1763782&lt;/ulink&gt;]. In October 2018, Roche reported that both programs had been discontinued; emactuzumab was no longer listed on the company's pipeline [&lt;ulink linkID="2083840" linkType="Reference"&gt;2083840&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The drug was also being investigated for the treatment of non-Hodgkin lymphoma. In December 2017, a phase I trial was planned to be initiated. By April 2018, the trial had been withdrawn due to a business decision [&lt;ulink linkID="1995270" linkType="Reference"&gt;1995270&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Emactuzumab was previously listed by Roche as being in phase II development. In July 2014, the drug was listed as being in phase II for pigmented villonodular synovitis (PVNS) [&lt;ulink linkID="1580367" linkType="Reference"&gt;1580367&lt;/ulink&gt;]; in April 2016, however, the development status was changed to phase I and PVNS was no longer listed as an indication [&lt;ulink linkID="1752925" linkType="Reference"&gt;1752925&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In July 2014, the company was planning to file a marketing application  for solid tumors and PVNS post   2017 [&lt;ulink linkID="1580365" linkType="Reference"&gt;1580365&lt;/ulink&gt;], [&lt;ulink linkID="1679888" linkType="Reference"&gt;1679888&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In May 2014, the US FDA granted the product Orphan designation for the treatment of PVNS and TGCT [&lt;ulink linkID="1559588" linkType="Reference"&gt;1559588&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Solid tumors&lt;/subtitle&gt;In October 2018, a &lt;ulink linkID="24773" linkType="Company"&gt;University of California San Francisco&lt;/ulink&gt;-sponsored, open-label, randomized, sequential-assigned, phase II trial (&lt;ulink linkID="357034" linkType="Protocol"&gt;NCT03708224&lt;/ulink&gt;; 177018; 18-25114) was planned to be initiated in November 2018 in the US, in patients (expected n = 60) with advanced non-virally associated SCCHN, to assess the efficacy of neoadjuvant &lt;ulink linkID="72699" linkType="Drug"&gt;atezolizumab&lt;/ulink&gt; in combination with emactuzumab. The primary endpoint was to determine the proportion of subjects with a &amp;gt;/= 40% increase in the CD3 counts and R0 resection rate after 2 years of treatment. At that time, the trial was expected to complete in November 2025 [&lt;ulink linkID="2086431" linkType="Reference"&gt;2086431&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2016, an open-label, multicenter, dose-escalation, phase Ib study (&lt;ulink linkID="260075" linkType="Protocol"&gt;NCT02760797&lt;/ulink&gt;; 	BP29427, 2015-004348-21) to evaluate the safety, pharmacokinetics, pharmacodynamics and therapeutic activity of emactuzumab and &lt;ulink linkID="94162" linkType="Drug"&gt;selicrelumab&lt;/ulink&gt; administered in combination in patients (expected n = 146) with advanced solid tumors, was initiated in the US, Belgium and France. At that time, the study was to complete in July 2018 [&lt;ulink linkID="1763782" linkType="Reference"&gt;1763782&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2015, a non-randomized, multicenter, open-label, dose escalation, phase Ib trial (&lt;ulink linkID="218713" linkType="Protocol"&gt;NCT02323191&lt;/ulink&gt;; BP29428, 2014-002428-29) with expansion phase in patients with advanced solid tumors (expected n=110)   in the US, France, Belgium, and Spain was initiated, to evaluate the safety and pharmacokinetics of iv emactuzumab in combination with iv &lt;ulink linkID="72699" linkType="Drug"&gt;atezolizumab&lt;/ulink&gt; (RG-7446;  MPDL-3280A). At that time, recruitment was yet to be initiated in the US and the trial was expected to complete in April 2018 [&lt;ulink linkID="1629586" linkType="Reference"&gt;1629586&lt;/ulink&gt;],  [&lt;ulink linkID="1629535" linkType="Reference"&gt;1629535&lt;/ulink&gt;], [&lt;ulink linkID="1629533" linkType="Reference"&gt;1629533&lt;/ulink&gt;]. In April 2017, the trial was expected to complete in September 2018. In October 2018, the trial was no longer recruiting (n = 310) and was expected to complete in December 2019 [&lt;ulink linkID="1629586" linkType="Reference"&gt;1629586&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2011, a non-randomized, open-label, multiple-ascending-dose, phase I study (&lt;ulink linkID="83366" linkType="Protocol"&gt;NCT01494688&lt;/ulink&gt;; BP27772; 2011-003394-28) was initiated in patients with advanced and/or metastatic solid tumors (expected n = 140) in the US and France, to assess the safety, pharmacokinetics, pharmacodynamics, and clinical activity of emactuzumab alone or in combination with &lt;ulink linkID="3803" linkType="Drug"&gt;paclitaxel&lt;/ulink&gt; [&lt;ulink linkID="1252963" linkType="Reference"&gt;1252963&lt;/ulink&gt;], [&lt;ulink linkID="1259334" linkType="Reference"&gt;1259334&lt;/ulink&gt;]. Secondary outcome measures would include changes in pharmacodynamic markers. An expansion phase would evaluate the drug as monotherapy in patients with PVNS and tenosynovial giant cell tumor (TGCT), ovarian cancer, and breast cancer. At that time, the study was scheduled to complete in July 2013 [&lt;ulink linkID="1252963" linkType="Reference"&gt;1252963&lt;/ulink&gt;]. In April 2013, biomarker data were presented at the 104th AACR Meeting in Washington DC [&lt;ulink linkID="1402026" linkType="Reference"&gt;1402026&lt;/ulink&gt;], [&lt;ulink linkID="1488927" linkType="Reference"&gt;1488927&lt;/ulink&gt;]. In November 2013, the trial was ongoing and expected to complete in September 2014 [&lt;ulink linkID="1252963" linkType="Reference"&gt;1252963&lt;/ulink&gt;]. In April 2014, preliminary biomarker data were presented at the 105th AACR meeting in San Diego, CA. Emactuzumab therapy was associated with profound reduction of tumor associated macrophages by 95%. Moreover, a trend for overall increase of CD8/CD4 T cell ratio in the tumor microenvironment was observed [&lt;ulink linkID="1541540" linkType="Reference"&gt;1541540&lt;/ulink&gt;]. In June 2014, data from 18 PVNS patients were presented at the 50th ASCO meeting in Chicago, IL. Emactuzumab was associated with reduction of CSF1R-positive cells in dose-dependent manner and depletion of non classical CD14dimCd16bright monocytes in peripheral blood as well. emactuzumab induced high objective clinical responses with early onset [&lt;ulink linkID="1561039" linkType="Reference"&gt;1561039&lt;/ulink&gt;]. In April 2015, the company planned to present updated data at ASCO 2015 [&lt;ulink linkID="1653537" linkType="Reference"&gt;1653537&lt;/ulink&gt;]. In June 2015, clinical data were presented at the 51st ASCO meeting in Chicago, IL. Emactuzumab induced durable responses in PVNS. Treatment-related adverse events included facial edema, asthenia, peripheral edema, pruritus, decreased appetite, rash, pyrexia, fatigue and diarrhea were reported [&lt;ulink linkID="1662552" linkType="Reference"&gt;1662552&lt;/ulink&gt;]. In April 2016, it was reported that recruitment completed in Q1 2016 (n = 216) [&lt;ulink linkID="1752925" linkType="Reference"&gt;1752925&lt;/ulink&gt;]. In December 2017, the trial was expected to complete in April 2018 [&lt;ulink linkID="1252963" linkType="Reference"&gt;1252963&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Non-Hodgkin lymphoma&lt;/subtitle&gt;In December 2017, an open-label, randomized, parallel group, phase I trial (&lt;ulink linkID="322392" linkType="Protocol"&gt;NCT03369964&lt;/ulink&gt;; GO40150; 2017-002587-41) was planned to be initiated in January 2018, in patients (expected n = 42) in the US with relapsed or refractory non-Hodgkin lymphoma, to assess the safety, pharmacology, and activity of &lt;ulink linkID="72699" linkType="Drug"&gt;atezolizumab&lt;/ulink&gt; in combination with immunotherapy agents (emactuzumab) with or without an anti-CD20 agent (ie &lt;ulink linkID="53227" linkType="Drug"&gt;obinutuzumab&lt;/ulink&gt;). At that time, the trial was expected to complete in August 2019. By April 2018, the trial had been withdrawn due to a business decision (no safety or efficacy concerns) [&lt;ulink linkID="1995270" linkType="Reference"&gt;1995270&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In June 2012, preclinical data were presented at the 29th International Conference on Advances in Applications of mAbs in Clinical Oncology in Mykonos, Greece. In MC38 colon cancer cells, emactuzumab, in combination with FOLFORI chemotherapy, caused tumor shrinkage, reduced angiogenesis and enhanced sensitivity to chemotherapy [&lt;ulink linkID="1306439" linkType="Reference"&gt;1306439&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;Emactuzumab has been designed to inhibit tumor-promoting M2 macrophages without affecting tumor-killing M1 macrophages [&lt;ulink linkID="1259417" linkType="Reference"&gt;1259417&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2013, the Pediatrics Committee (PDCO) of the EMA planned to discuss the applicability of a class waiver at a meeting scheduled for May 17, 2013 [&lt;ulink linkID="1421639" linkType="Reference"&gt;1421639&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="FR">France</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3531">Pigmented villonodular synovitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-04-19T00:00:00.000Z</StatusDate><Source id="1752925" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-10-17T00:00:00.000Z</StatusDate><Source id="2083840" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3713">Advanced solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-10-17T00:00:00.000Z</StatusDate><Source id="2083840" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3713">Advanced solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-10-17T00:00:00.000Z</StatusDate><Source id="2083840" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="FR">France</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-12-20T00:00:00.000Z</StatusDate><Source id="1252963" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="FR">France</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3531">Pigmented villonodular synovitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-12-31T00:00:00.000Z</StatusDate><Source id="1252963" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-12-20T00:00:00.000Z</StatusDate><Source id="1252963" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-01-19T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-12-12T00:00:00.000Z</StatusDate><Source id="1995270" type="TRIALREG"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00510"><Name>CSF-1</Name><SwissprotNumbers><Swissprot>P07333</Swissprot><Swissprot>P09581</Swissprot><Swissprot>P13369</Swissprot><Swissprot>Q00495</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="2224667" number="WO-2011070024" title="Antibodies binding preferentially human CSF1R extracellular domain 4 and their use"></PatentFamily><PatentFamily id="2549336" number="WO-2013087699" title="Antibodies against human CSF-1R and uses thereof"></PatentFamily><PatentFamily id="2590935" number="WO-2013132044" title="Combination therapy of antibodies against human CSF-1R and uses thereof"></PatentFamily><PatentFamily id="2818774" number="WO-2014173814" title="Combination therapy of antibodies against human csf-1r and tlr9 agonist"></PatentFamily><PatentFamily id="3963465" number="WO-2018036852" title="Intermittent dosing of an anti-CSF-1R antibody in combination with macrophage activating agent"></PatentFamily><PatentFamily id="4104569" number="WO-2018115051" title="Treatment of tumors with an anti-CSF-1R antibody in combination with an anti-PD-L1 antibody after failure of anti-PD-L1/PD1 treatment"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="14">Tentative</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cargill Inc" id="15307"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Roche Holding AG" id="19446"></CompanyLink><CountAsOwner>6</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput>